title: [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
abstract: With the introduction of targeted drug therapies, a paradigm shift for the treatment of metastatic renal cell carcinoma has taken place. New compounds like sunitinib, sorafenib, bevacizumab and temsirolimus have become established as new therapeutic standards to replace the use of cytokines as standard therapy. Recently, these substances have been complemented by everolimus and pazopanib. An interdisciplinary consensus conference was held to discuss which criteria to consider when using these drugs (treatment sequence) and what questions remain unanswered based on the current study situation (open questions). Results from the 2009 conference provided the basis for the 2010 meeting. The results of the 2010 conference are presented as short theses.
authors: Klinik für Urologie, Charité - Universitätsmedizin Berlin, Germany. Kurt.miller@charite.de
authors: K
authors: K
authors: Miller
authors: L
authors: L
authors: Bergmann
authors: J
authors: J
authors: Gschwend
authors: U
authors: U
authors: Keilholz
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000009:adverse effects / Q000627:therapeutic use; D000068258:Bevacizumab; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality / Q000601:surgery; D017326:Clinical Trials, Phase III as Topic; D003131:Combined Modality Therapy; D003299:Cooperative Behavior; D016207:Cytokines / Q000009:adverse effects / Q000627:therapeutic use; D018450:Disease Progression; D000068338:Everolimus; D019317:Evidence-Based Medicine; D006801:Humans; D007191:Indazoles; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use; D033183:Interdisciplinary Communication; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality / Q000601:surgery; D058990:Molecular Targeted Therapy / Q000379:methods*; D009536:Niacinamide / Q000031:analogs & derivatives; D010348:Patient Care Team; D010671:Phenylurea Compounds; D010982:Platelet-Derived Growth Factor / Q000037:antagonists & inhibitors / Q000235:genetics; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use; D011758:Pyrroles / Q000009:adverse effects / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077157:Sorafenib; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use; D000077210:Sunitinib; D015996:Survival Rate; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000235:genetics
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D016207:Cytokines; D007191:Indazoles; D007211:Indoles; D010671:Phenylurea Compounds; D010982:Platelet-Derived Growth Factor; D011725:Pyridines; D011743:Pyrimidines; D011758:Pyrroles; D013449:Sulfonamides; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D009536:Niacinamide; D000068258:Bevacizumab; C401859:temsirolimus; C516667:pazopanib; D000068338:Everolimus; D000077157:Sorafenib; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D000077210:Sunitinib; D020123:Sirolimus